Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.69 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.69 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.62 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.62 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.62 |
| ▸ | PARG | Q86W56 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419143 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL19493160 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL29476738 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL23982340 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL3163036 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL250252 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL250251 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL12932304 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL29476737 | 0.99 | P2RX1 (0.70) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| SCHEMBL22498804 | 0.98 | P2RX1 (0.68) | P2RX1P2RX3P2RX2RNASELP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118992-A1 | NUCLEOTIDE ANALOGUES | R.G.C.C.Holdings AG (CH) | 2023-04-20 | — | — | US | disclosed |
| EP-4125912-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191236-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118992-A1 | NUCLEOTIDE ANALOGUES | PNP, NUDT1, RNGTT | P2RX1 137/4885P2RX3 228/4885P2RX2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.